<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376528</url>
  </required_header>
  <id_info>
    <org_study_id>OS-3</org_study_id>
    <nct_id>NCT04376528</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy</brief_title>
  <official_title>Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome
      induced by mycophenolate mofetil versus cyclosporin A
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The percentage of patients in biochemical remission, defined as normalization of serum ALT and IgG levels after 24 weeks of treatment, per treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Partial remission, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) serum levels &gt;1x Upper Limit of Normal (ULN) and &lt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Minimal response, defined as decrease of ALT or AST serum levels but still &gt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>up to 6 months</time_frame>
    <description>defined as no improvement or increase of ALT or AST serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver stiffness</measure>
    <time_frame>up to 6 months</time_frame>
    <description>liver stiffness will be measured by shear-wave elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Drug related side-effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Hepatitis, Autoimmune</condition>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Cyclosporin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)</description>
    <arm_group_label>Cyclosporin A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18-70 years;

          2. Diagnosed with PBC-AIH overlap syndrome according to Paris criteria;

          3. Patients have a nonresponse to azathioprine;

          4. The WBC count ≥2.5x10^9/L and platelet count ≥50x10^9/L.

          5. Agreed to participate in the trial, and assigned informed consent;

        Exclusion Criteria:

          1. The presence of hepatitis A, B, C, D, or E virus infection;

          2. Patients with presence of serious decompensated cirrhosis;

          3. Patients have a history of glucocorticoid or immunosuppressant medication before
             enrollment;

          4. Liver damage caused by other reasons: such as primary sclerosing cholangitis,
             non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease.

          5. Pregnant and breeding women and women of childbearing age in need of reproduction

          6. Severe disorders of other vital organs, such as severe heart failure, cancer;

          7. Patients with presence of renal insufficiency;

          8. Parenteral administration of blood or blood products within 6 months before screening;

          9. Recent treatment with drugs having known liver toxicity;

         10. Taken part in other clinic trials within 6 months before enrollment.

         11. Patients who are allergic to these drugs;

         12. Uncontrolled infection and hypertension ;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Yang, Master degree</last_name>
    <phone>+86 13518178110</phone>
    <email>yangli_hx@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Yang</last_name>
    <phone>+86 13518178110</phone>
    <email>yangli_hx@scu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
    <mesh_term>Undifferentiated Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

